Table 1. Characteristics of CML Patients Treated with Triptolide in vitro.

						in vitro triptolide treatment
patient	blast %	sample source	in vivo treatments and responses at the time of sampling	Bcr-Abl mutation status	BC lineage	IC50 (nM)	western blot
1	49	PB	Resistant to imatinib and nilotinib	M351T	myeloid	32.5	XIAP
2	62	PB	Resistant to imatinib	wt	myeloid	178.9	XIAP, Mcl-1, Bcr-Abl
3	80	PB	Resistant to imatinib, nilotinib and other therapies	wt	myeloid	84.1	-
3a	83	BM		wt		87.9	-
4	91	PB	Hydrea, later died	wt	myeloid	43.0	-
5	87	PB	no cytogenetic remission with imatinib, dasatinib, or nilotinib	wt	myeloid	111.7	XIAP, Mcl-1, Bcr-Abl
6	64	PB	failed imatinib and other chemotherapies	wt	bilineage	206.2	XIAP, Mcl-1, Bcr-Abl